SCHEMBL26416118

SCHEMBL26416118

Cc1csc(N2CCC(NI)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ DPP4 P27487 1/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ OGA O60502 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.37
▸ POLB P06746 2/20 0.36
▸ MAPT P10636 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10136842 0.80 HRH3 (0.49) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL7676465 0.80 HRH3 (0.42) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL13634230 0.76 HRH3 (0.55) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL3559247 0.76 HRH3 (0.55) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL12988798 0.76 HRH3 (0.52) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL3511935 0.76 L3MBTL1 (0.54) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL4472290 0.76 L3MBTL1 (0.54) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL458365 0.75 HRH3 (0.48) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL4469579 0.74 SMN1; SMN2 (0.53) HRH3L3MBTL1DPP4SMN1; SMN2OGA
SCHEMBL3555940 0.74 HRH3 (0.44) HRH3L3MBTL1DPP4SMN1; SMN2OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS HRH3 4589/4885L3MBTL1 183/4885DPP4 4319/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS HRH3 4589/4885L3MBTL1 183/4885DPP4 4319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback